Ribavirin administration to infants receiving mechanical ventilation.

Area of Science:

• Pediatric critical care medicine
• Infectious diseases
• Respiratory medicine

Background:

• Bronchiolitis is a common viral respiratory infection in infants, often leading to severe respiratory failure.
• Infants with underlying cardiac or pulmonary conditions are at higher risk for severe bronchiolitis and require mechanical ventilation.
• Antiviral therapy options for severe infant bronchiolitis remain limited.

Purpose of the Study:

• To evaluate the safety and efficacy of aerosolized ribavirin administration in infants with severe bronchiolitis requiring mechanical ventilation.
• To describe a specialized method for delivering aerosolized ribavirin to mechanically ventilated infants.
• To assess the feasibility of monitoring and managing patients during this treatment.

Main Methods:

• A cohort of 12 infants with severe bronchiolitis and respiratory failure on mechanical ventilation received aerosolized ribavirin.
• A specific administration protocol was developed, including timed circuit changes to prevent drug precipitation, frequent endotracheal suctioning, and continuous patient/ventilator monitoring.
• Treatment success and patient tolerance were the primary outcomes assessed.

Main Results:

• All 12 infants successfully completed the aerosolized ribavirin treatment.
• The developed administration and monitoring method effectively prevented circuit obstruction and allowed for safe drug delivery.
• No adverse events related to ribavirin administration were reported in the study cohort.

Conclusions:

• Aerosolized ribavirin can be safely and effectively administered to infants with severe bronchiolitis receiving mechanical ventilation.
• The specialized method for drug delivery and patient monitoring is crucial for successful treatment in this vulnerable population.
• This approach offers a potential therapeutic option for severe cases of infant bronchiolitis, particularly in high-risk infants.